Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, Taroh Satoh, Federico Cappuzzo, John Souglakos, Dalia Ercan, Andrew Rogers, Massimo Roncalli, Masayuki Takeda, Yasuhito Fujisaka, Juliet Philips, Toshio Shimizu, Osamu Maenishi, Yonggon Cho, Jason Sun, Annarita Destro, Koichi Taira, Koji Takeda, Takafumi OkabeJeffrey Swanson, Hiroyuki Itoh, Minoru Takada, Eugene Lifshits, Kiyotaka Okuno, Jeffrey A. Engelman, Ramesh A. Shivdasani, Kazuto Nishio, Masahiro Fukuoka, Marileila Varella-Garcia, Kazuhiko Nakagawa, Pasi A. Jänne

Research output: Contribution to journalArticle

Abstract

Cetuximab, an antibody directed against the epidermal growth factor receptor, is an effective clinical therapy for patients with colorectal, head and neck, and non-small cell lung cancer, particularly for those with KRAS and BRAF wild-type cancers. Treatment in all patients is limited eventually by the development of acquired resistance, but little is known about the underlying mechanism. Here, we show that activation of ERBB2 signaling in cell lines, either through ERBB2 amplification or through heregulin up-regulation, leads to persistent extracellular signal-regulated kinase 1/2 signaling and consequently to cetuximab resistance. Inhibition of ERBB2 or disruption of ERBB2/ERBB3 heterodimerization restores cetuximab sensitivity in vitro and in vivo. A subset of colorectal cancer patients who exhibit either de novo or acquired resistance to cetuximab-based therapy has ERBB2 amplification or high levels of circulating heregulin. Collectively, these findings identify two distinct resistance mechanisms, both of which promote aberrant ERBB2 signaling, that mediate cetuximab resistance. Moreover, these results suggest that ERBB2 inhibitors, in combination with cetuximab, represent a rational therapeutic strategy that should be assessed in patients with cetuximab-resistant cancers.

Original languageEnglish
JournalScience Translational Medicine
Volume3
Issue number99
Publication statusPublished - Sep 7 2011

Fingerprint

Antibodies
Neuregulin-1
Therapeutics
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Cetuximab
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Colorectal Neoplasms
Neoplasms
Neck
Up-Regulation
Head
Cell Line

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., ... Jänne, P. A. (2011). Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Science Translational Medicine, 3(99).

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. / Yonesaka, Kimio; Zejnullahu, Kreshnik; Okamoto, Isamu; Satoh, Taroh; Cappuzzo, Federico; Souglakos, John; Ercan, Dalia; Rogers, Andrew; Roncalli, Massimo; Takeda, Masayuki; Fujisaka, Yasuhito; Philips, Juliet; Shimizu, Toshio; Maenishi, Osamu; Cho, Yonggon; Sun, Jason; Destro, Annarita; Taira, Koichi; Takeda, Koji; Okabe, Takafumi; Swanson, Jeffrey; Itoh, Hiroyuki; Takada, Minoru; Lifshits, Eugene; Okuno, Kiyotaka; Engelman, Jeffrey A.; Shivdasani, Ramesh A.; Nishio, Kazuto; Fukuoka, Masahiro; Varella-Garcia, Marileila; Nakagawa, Kazuhiko; Jänne, Pasi A.

In: Science Translational Medicine, Vol. 3, No. 99, 07.09.2011.

Research output: Contribution to journalArticle

Yonesaka, K, Zejnullahu, K, Okamoto, I, Satoh, T, Cappuzzo, F, Souglakos, J, Ercan, D, Rogers, A, Roncalli, M, Takeda, M, Fujisaka, Y, Philips, J, Shimizu, T, Maenishi, O, Cho, Y, Sun, J, Destro, A, Taira, K, Takeda, K, Okabe, T, Swanson, J, Itoh, H, Takada, M, Lifshits, E, Okuno, K, Engelman, JA, Shivdasani, RA, Nishio, K, Fukuoka, M, Varella-Garcia, M, Nakagawa, K & Jänne, PA 2011, 'Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.', Science Translational Medicine, vol. 3, no. 99.
Yonesaka, Kimio ; Zejnullahu, Kreshnik ; Okamoto, Isamu ; Satoh, Taroh ; Cappuzzo, Federico ; Souglakos, John ; Ercan, Dalia ; Rogers, Andrew ; Roncalli, Massimo ; Takeda, Masayuki ; Fujisaka, Yasuhito ; Philips, Juliet ; Shimizu, Toshio ; Maenishi, Osamu ; Cho, Yonggon ; Sun, Jason ; Destro, Annarita ; Taira, Koichi ; Takeda, Koji ; Okabe, Takafumi ; Swanson, Jeffrey ; Itoh, Hiroyuki ; Takada, Minoru ; Lifshits, Eugene ; Okuno, Kiyotaka ; Engelman, Jeffrey A. ; Shivdasani, Ramesh A. ; Nishio, Kazuto ; Fukuoka, Masahiro ; Varella-Garcia, Marileila ; Nakagawa, Kazuhiko ; Jänne, Pasi A. / Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. In: Science Translational Medicine. 2011 ; Vol. 3, No. 99.
@article{35eaf6019c6d44c985f4da73b29d3be8,
title = "Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.",
abstract = "Cetuximab, an antibody directed against the epidermal growth factor receptor, is an effective clinical therapy for patients with colorectal, head and neck, and non-small cell lung cancer, particularly for those with KRAS and BRAF wild-type cancers. Treatment in all patients is limited eventually by the development of acquired resistance, but little is known about the underlying mechanism. Here, we show that activation of ERBB2 signaling in cell lines, either through ERBB2 amplification or through heregulin up-regulation, leads to persistent extracellular signal-regulated kinase 1/2 signaling and consequently to cetuximab resistance. Inhibition of ERBB2 or disruption of ERBB2/ERBB3 heterodimerization restores cetuximab sensitivity in vitro and in vivo. A subset of colorectal cancer patients who exhibit either de novo or acquired resistance to cetuximab-based therapy has ERBB2 amplification or high levels of circulating heregulin. Collectively, these findings identify two distinct resistance mechanisms, both of which promote aberrant ERBB2 signaling, that mediate cetuximab resistance. Moreover, these results suggest that ERBB2 inhibitors, in combination with cetuximab, represent a rational therapeutic strategy that should be assessed in patients with cetuximab-resistant cancers.",
author = "Kimio Yonesaka and Kreshnik Zejnullahu and Isamu Okamoto and Taroh Satoh and Federico Cappuzzo and John Souglakos and Dalia Ercan and Andrew Rogers and Massimo Roncalli and Masayuki Takeda and Yasuhito Fujisaka and Juliet Philips and Toshio Shimizu and Osamu Maenishi and Yonggon Cho and Jason Sun and Annarita Destro and Koichi Taira and Koji Takeda and Takafumi Okabe and Jeffrey Swanson and Hiroyuki Itoh and Minoru Takada and Eugene Lifshits and Kiyotaka Okuno and Engelman, {Jeffrey A.} and Shivdasani, {Ramesh A.} and Kazuto Nishio and Masahiro Fukuoka and Marileila Varella-Garcia and Kazuhiko Nakagawa and J{\"a}nne, {Pasi A.}",
year = "2011",
month = "9",
day = "7",
language = "English",
volume = "3",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "99",

}

TY - JOUR

T1 - Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

AU - Yonesaka, Kimio

AU - Zejnullahu, Kreshnik

AU - Okamoto, Isamu

AU - Satoh, Taroh

AU - Cappuzzo, Federico

AU - Souglakos, John

AU - Ercan, Dalia

AU - Rogers, Andrew

AU - Roncalli, Massimo

AU - Takeda, Masayuki

AU - Fujisaka, Yasuhito

AU - Philips, Juliet

AU - Shimizu, Toshio

AU - Maenishi, Osamu

AU - Cho, Yonggon

AU - Sun, Jason

AU - Destro, Annarita

AU - Taira, Koichi

AU - Takeda, Koji

AU - Okabe, Takafumi

AU - Swanson, Jeffrey

AU - Itoh, Hiroyuki

AU - Takada, Minoru

AU - Lifshits, Eugene

AU - Okuno, Kiyotaka

AU - Engelman, Jeffrey A.

AU - Shivdasani, Ramesh A.

AU - Nishio, Kazuto

AU - Fukuoka, Masahiro

AU - Varella-Garcia, Marileila

AU - Nakagawa, Kazuhiko

AU - Jänne, Pasi A.

PY - 2011/9/7

Y1 - 2011/9/7

N2 - Cetuximab, an antibody directed against the epidermal growth factor receptor, is an effective clinical therapy for patients with colorectal, head and neck, and non-small cell lung cancer, particularly for those with KRAS and BRAF wild-type cancers. Treatment in all patients is limited eventually by the development of acquired resistance, but little is known about the underlying mechanism. Here, we show that activation of ERBB2 signaling in cell lines, either through ERBB2 amplification or through heregulin up-regulation, leads to persistent extracellular signal-regulated kinase 1/2 signaling and consequently to cetuximab resistance. Inhibition of ERBB2 or disruption of ERBB2/ERBB3 heterodimerization restores cetuximab sensitivity in vitro and in vivo. A subset of colorectal cancer patients who exhibit either de novo or acquired resistance to cetuximab-based therapy has ERBB2 amplification or high levels of circulating heregulin. Collectively, these findings identify two distinct resistance mechanisms, both of which promote aberrant ERBB2 signaling, that mediate cetuximab resistance. Moreover, these results suggest that ERBB2 inhibitors, in combination with cetuximab, represent a rational therapeutic strategy that should be assessed in patients with cetuximab-resistant cancers.

AB - Cetuximab, an antibody directed against the epidermal growth factor receptor, is an effective clinical therapy for patients with colorectal, head and neck, and non-small cell lung cancer, particularly for those with KRAS and BRAF wild-type cancers. Treatment in all patients is limited eventually by the development of acquired resistance, but little is known about the underlying mechanism. Here, we show that activation of ERBB2 signaling in cell lines, either through ERBB2 amplification or through heregulin up-regulation, leads to persistent extracellular signal-regulated kinase 1/2 signaling and consequently to cetuximab resistance. Inhibition of ERBB2 or disruption of ERBB2/ERBB3 heterodimerization restores cetuximab sensitivity in vitro and in vivo. A subset of colorectal cancer patients who exhibit either de novo or acquired resistance to cetuximab-based therapy has ERBB2 amplification or high levels of circulating heregulin. Collectively, these findings identify two distinct resistance mechanisms, both of which promote aberrant ERBB2 signaling, that mediate cetuximab resistance. Moreover, these results suggest that ERBB2 inhibitors, in combination with cetuximab, represent a rational therapeutic strategy that should be assessed in patients with cetuximab-resistant cancers.

UR - http://www.scopus.com/inward/record.url?scp=84862833240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862833240&partnerID=8YFLogxK

M3 - Article

C2 - 21900593

VL - 3

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 99

ER -